Fragment-based discovery of potent ERK2 pyrrolopyrazine inhibitors.
Burdick, D.J., Wang, S., Heise, C., Pan, B., Drummond, J., Yin, J., Goeser, L., Magnuson, S., Blaney, J., Moffat, J., Wang, W., Chen, H.(2015) Bioorg Med Chem Lett 25: 4728-4732
- PubMed: 26338362 
- DOI: 10.1016/j.bmcl.2015.08.048
- Primary Citation of Related Structures:  
4QP1, 4QP2, 4QP3, 4QP4, 4QP6, 4QP7, 4QP8, 4QP9, 4QPA - PubMed Abstract: 
A fragment-based lead discovery approach was used to discover novel ERK2 inhibitors. The crystal structure of N-benzyl-9H-purin-6-amine 1 in complex with ERK2 elucidated its hinge-binding mode. In addition, the simultaneous binding of an imidazole molecule adjacent to 1 suggested a direction for fragment expansion ...